Skip to main content

Table 2 Average annual per patient use (95% CI) of hospital services by ART and AIDS status at AMH (2004/5)

From: Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia

 

Non-ART

ART

Services categories

Total

non-AIDS

AIDS

Total

non-AIDS

AIDS

Outpatient services

PYO* = 80.82

PYO = 75.24

PYO = 5.58

PYO = 221.98

PYO = 181.13

PYO = 40.85

Consultation at HIV Clinic

4.6(4.3–5.0)

4.5(4.1–4.9)

5.9(4.0–7.9)

11.4(11.0–11.7)

11.4(11.0–11.8)

11.3(10.5–12.1)

Laboratory

      

    Haematology (CBC)

4.4(4.0–4.8)

4.3(3.9–4.9)

5.4(3.5–7.3)

3.1(2.96–3.2)

3(2.9–3.2)

3.3(2.9–3.7)

    Clinical chemistry

1.1(0.9–1.3)

1.1(0.8–1.3)

1.3(0.1–2.4)

3.1(2.9–3.2)

3.1(2.9–3.2)

3.2(2.8–3.6)

    CD4

0.0

0

0

0.4(0.3–0.4)

0.4(0.3–0.4)

0.3(0.2–0.5)

    Other tests

0.3(0.2–0.5)

0.3(0.2–0.4)

0.7(0.1–1.6)

0.3(0.2–0.4)

0.3(0.2–0.4)

0.4(0.2–0.5)

Imaging

0.7(0.5–0.9)

0.6(0.5–0.8)

1.6(0.6–2.6)

0.1(0.05–0.13)

0.1(0.0–0.1)

0.1(0.0–0.2)

Anti Retroviral drugs

      

    Zudovudine (300 mg)

0.0

0

0

28.7(13.3–44.1)

33.4(14.6–52.1)

8.3(0.0–16.7)

    3TC (150 mg)

0.0

0

0

548.2(515.2–581.1)

551.1(515.2–587.0)

535.0(451–618.9)

    Stavudine (d4T; 40 mg)

0.0

0

0

205.1(162.4–247.8)

224.3(175.3–273.2)

120.4(44.9–195.8)

    Stavudine (d4T; 30 mg)

0.0

0

0

317.7(268.2–367.1)

297.7(242.6–352.8)

406.2(294.7–517.8)

    Neverapine (200 mg)

0.0

0

0

401.2(353–449.4)

402.8(349.4–456.1)

394.3(277.9–510.7)

    Effavirenze (600 mg)

0.0

0

0

113.3(89.6–137.0)

112.1(85.7–138.4)

118.9(63–174.8)

    Zudovidine+3TC 450 mg

0.0

0

0

88.3(59.9–116.7)

88.6(57.2–120.1)

86.8(18.8–154.8)

Non-ARV drugs 1

10.9(8.4–13.3)

10.0(7.6–12.4)

22.4(7.8–37.0)

3.8(3.1–4.5)

3.9(3.0–4.7)

3.5(2.6–4.5)

Inpatient services

n = 33

n = 13

n = 20

n = 25

n = 19

n = 6

Laboratory

      

    Haematology (CBC)

0.9(0.7–1.0)

0.9(0.5–1.2)

0.9(0.6–1.1)

0.7(0.5–0.9)

0.7(0.5–1.0)

0.7(0.1–1.2)

    Clinical chemistry

0.4(0.2–0.6)

0.3(0.1–0.7)

0.5(0.2–0.7)

0.4(0.2–0.7)

0.5(0.2–0.7)

0.3(-0.2–0.9)

    CD4

0.00

0

0

0.08(0.03–0.19)

0.1(0.05–0.3)

0

    Other tests

1.3(0.8–1.7)

1.31(0.5–2.1)

1.3(0.7–1.6)

0.5(0.1–0.9)

0.5(0.1–0.9)

0.7(0.6–1.9)

Imaging

0.5(0.3–0.7)

0.4(0.01–0.8)

0.6(0.3–0.9)

0.08(0.03–0.19)

0.1(0.06–0.16)

0.17(0.06–0.60)

Non-ARVdrug 1

11.3(8.8–13.9)

11.2(7.7–14.7)

11.4(7.6–15.2)

5.5(3.9–7.1)

5.7(3.7–7.6)

5.0(0.9–9.0)

Mean number of inpatient days

17.6(13.1–22.1)

12.2(6.2–18.1)

21.1(14.9–27.3)

5.6(4.4–6.9

4.5(3.5–5.6)

9.2(5.7–12.6)

  1. *Person year observation
  2. 1 Utilization is expressed in terms of US $.